KROS•benzinga•
Truist Securities Maintains Buy on Keros Therapeutics, Lowers Price Target to $25
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on April 9, 2025 by benzinga